Purpose: To describe the two-year outcome of trabeculectomy in cytomegalovirus(CMV) anterior uveitis(AU).
Methods: Records of 29 eyes of 29 consecutive CMV AU patients undergoing MMC-augmented trabeculectomy for uncontrolled IOP despite maximal tolerated topical medications were retrospectively reviewed. Treatment success was defined as IOP≤21 mmHg with same or reduced number of IOP-lowering medications compared to baseline, without systemic acetazolamide or further interventions for uncontrolled IOP.
Results: Treatment success was 79.3% (23/29) at 24 months. Both median IOP and number of IOP-lowering medications dropped significantly from baseline (p < .01 and p < .001, all time-points, Wilcoxon sign-rank test, respectively), with 63.2% and 19.0% reduction in AU relapse/year and steroid use(p = .001 and 0.03, respectively), without sight-threatening sequelae. At 24 months, AU frequency was not significantly different between successful cases with and without ≥12-month use of topical ganciclovir (p = .51, Mann-Whitney U test).
Conclusion: MMC-augmented trabeculectomy was efficacious for IOP control in nearly 80% of CMV AU cases over two years.
Keywords: Cytomegalovirus; hypertensive anterior uveitis; trabeculectomy; uveitic glaucoma; viral anterior uveitis.